The other ‘D’ in DE&I

How companies can work to include people with disabilities into broader equity aims.

By Taren Grom • Nov. 4, 2022

‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.

By Michael Gibney • Nov. 3, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Woman of the Week: City of Hope’s Gulden Mesara

Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

By Taren Grom • Nov. 2, 2022

Tuberculosis patients haven’t seen new treatments in 40 years – now Merck and Gates MRI have teamed up to change that

The Bill & Melinda Gates Medical Research Institute’s clinical development leader talks about its new licensing deal with Merck.

By Alexandra Pecci • Nov. 1, 2022

While DCTs get all the hype, some industry insiders say the future is a digital hybrid

Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

By Michael Gibney • Nov. 1, 2022

Tips for tackling trial recruitment and retention woes in oncology

How new tools are helping companies find and keep cancer patients in clinical studies.

By Kelly Bilodeau • Oct. 31, 2022

Vaccine chief’s exit spurs new slate of GSK executive changes

How the pharma giant is consolidating power as it looks to become a dominant force in the vaccine market. 

By Karissa Waddick • Oct. 31, 2022

Pharma execs on creating a better workplace culture

Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

By Taren Grom • Oct. 28, 2022

Riches, rags, riches: Is Biogen the Cinderella of biotechs?

Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

By Michael Gibney • Oct. 27, 2022

Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann

The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.

By Taren Grom • Oct. 26, 2022

Nobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development

The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.

By Karissa Waddick • Oct. 26, 2022

Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

By Meagan Parrish • Oct. 25, 2022

Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning

In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.

By Michael Gibney • Oct. 24, 2022

What’s keeping pharma leaders up at night

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

By Taren Grom • Oct. 21, 2022

J&J reveals just how much economic turbulence is affecting Big Pharma

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

By Michael Gibney • Oct. 20, 2022

5 impactful drug trial failures from the last year

Major recent trial flops and what they mean for companies, patients and the industry.

By Meagan Parrish • Oct. 19, 2022

Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps

Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.

By Karissa Waddick • Oct. 18, 2022

A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers

Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

By Kelly Bilodeau • Oct. 18, 2022

The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan

Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.

By Meagan Parrish • Oct. 17, 2022

He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

By Michael Gibney • Oct. 17, 2022

What’s your leadership brand?

Pharma industry leaders share their brand personas.

By Taren Grom • Oct. 14, 2022

Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

By Kelly Bilodeau • Oct. 13, 2022

Robotic pills could open a world of possibilities for the biologics market

As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

By Karissa Waddick • Oct. 13, 2022

Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

By Meagan Parrish • Oct. 12, 2022

Woman of the Week: HBA’s Nikki Jones

As the Healthcare Businesswomen’s Association’s first chief people and DEI officer, Jones is poised to tackle pay gap inequity, systemic gender bias and leadership barriers impeding women of color.

By Taren Grom • Oct. 12, 2022